Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity Clinical Trial

Official title:

A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02808104
• Other study ID #: NLS-1001
• Status: Completed
• Phase: Phase 2
• First received: June 15, 2016
• Last updated: April 4, 2017
• Start date: August 2016
• Est. completion date: March 28, 2017

Study information

• Verified date: April 2017
• Source: NLS-1 Pharma Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a controlled release formulation of mazindol is more effective than a placebo in the treatment of Attention Hyperactivity Disorder (ADHD) in adults.

Description:

This study is an outpatient, randomized, double-blind, placebo-controlled trial in which adult subjects with ADHD will be randomized to either oral mazindol controlled release or placebo once daily. Subjects will be treated with study medication or placebo for 6 weeks with visits occurring weekly to measure efficacy and any adverse events with adjustment of medication dosing as necessary.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: March 28, 2017
• Est. primary completion date: March 28, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subject has a primary diagnosis of ADHD established by a comprehensive psychiatric evaluation based on DSM-5 criteria.

• Subject is functioning at an appropriate level intellectually as judged by the investigator.

• Subject has a minimum baseline score of 28 at screen and at baseline using the ADHD-RS-DSM5

• Subject has a minimum score of 4 (moderate) on the CGI-S at screening.

• Women of child-bearing potential must be non-pregnant, non-lactating, and agree to be on an acceptable method of contraception. Acceptable methods of contraception include intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable), and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.

• In good general physical health as determined by medical history, a baseline physical examination, vital signs, clinical laboratory tests and electrocardiogram (ECG) measurement.

• Subject is fluent in written and spoken English and is willing and able to sign written informed consent prior to receipt of any study medication or beginning study procedures.

• Subject is willing and able to follow instructions, comply with the protocol requirements and make all required study visits.

Exclusion Criteria:

• Any primary DSM-5 Axis I disorder other than ADHD or any comorbid DSM-5 disorder that currently requires treatment.

• Lifetime history of any DSM-5 bipolar disorder

• Treatment with medications for any psychiatric or neurologic condition (e.g., amphetamines, MPH products, antidepressants, antipsychotics, mood stabilizers, anti-epileptics) or pressor agents concurrently or within 14 days of randomization.

• Concurrent medical illness that would interfere with the conduct of the study in the opinion of the investigator.

• History of significant cardiovascular disease, structural cardiac abnormality, cardiomyopathy, heart failure, serious heart rhythm abnormalities, coronary heart disease, transient ischemic attack or stroke, or other serious cardiac problems.

• Family history of sudden cardiac death.

• Clinically significant ECG abnormality or a QTc (Bazett correction) interval >450 msec.

• Resting sitting systolic blood pressure > 150 mm Hg or diastolic blood pressure > 90 mm Hg.

• BMI <18 or >40 kg/m2.

• Other medications that have CNS effects on cognition or attention (e.g., sedating antihistamines or decongestants).

• Positive drug screen (UDS) at screening (with the exception of current ADHD medication).

• Concomitant use of sensitive CYPA4/5 or CYP2D6 substrates with narrow therapeutic indices.

• Pregnant or lactating.

• Ongoing psychotherapeutic treatment for the treatment of ADHD begun less than three months before entry into this study.

• Recent or current DSM-5 Substance Use Disorder of moderate or greater severity (i.e., > 4 SUD symptoms), excluding nicotine.

• Suicidal ideation within past 3 months, suicidal behavior within the past year, or a C-SSRS score of 3, 4 or 5 on ideation item.

• Evidence of any out-of-range laboratory value at screening that has not been reviewed, approved and documented as not clinically significant by the Study Investigator.

• A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis), or any known/suspected hypersensitivity to any form of mazindol.

• Any other condition or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening that, in the opinion of the Study Investigator, would make the subject unsuitable for the study or put them at additional risk.

• Treatment with an investigational drug within 30 days preceding the first dose of study medication.

Related Conditions & MeSH terms

• Attention Deficit Disorder With Hyperactivity
• Disease
• Hyperkinesis

Intervention

Drug:
• mazindol

Locations

Country	Name	City	State
United States	Memorial Park Psychiatry / Bayou City Research	Houston	Texas
United States	CNS Healthcare	Jacksonville	Florida
United States	South Shore Psychiatric Services	Marshfield	Massachusetts
United States	Clinical Neuroscience Solutions	Memphis	Tennessee
United States	AVIDA Clinic	Newport Beach	California
United States	Rochester Center for Behavorial Medicine	Rochester Hills	Michigan
United States	Midwest Research Group / St. Charles Psychiatric Associates	St. Charles	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
NLS-1 Pharma Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ADHD Rating Scale		weekly rating up to six weeks
Secondary	Clinical Global Improvement Scale		weekly rating up to six weeks